BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

TEL AVIV, Israel, Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has gra... Biopharmaceuticals, Oncology, FDA BioLineRx, BL-8040, CXCR4, Pancreatic Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news